News

Santé log1h
Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées
L’avis positif du CHMP se base sur les données de l’essai de Phase III CABINET, qui a consisté à étudier Cabometyx par rapport à un placebo chez des personnes atteintes de TNEp ou TNEep avancées, dont ...
Santé log1h
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen ...
Santé log1h
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
The positive CHMP opinion is based on data from the CABINET Phase III trial, which investigated Cabometyx versus placebo in people living with advanced pNETs or epNETs, whose disease had progressed ...
Santé log3h
NEUROBLASTOME : Nouvelle stratégie de différenciation pour un cancer pédiatrique grave
Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...
Santé log3h
NANOTHÉRAPIE : Sucrée, elle ensuque les amyloïdes toxiques
Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...
Santé log4h
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
NurExone’s acceptance into the prestigious HTH Accelerator Program will support the Company’s expansion into the U.S. market following the establishment of Exo-top Inc. (“ Exo-TOP ”), the Company’s ...
Santé log4h
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) Approval based on pivotal results showing improvements in sustained disease ...
Santé log4h
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...
Santé log10h
HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support
GLP-1 medications have emerged as a physician-supervised option for individuals managing obesity or weight-related conditions ...
Santé log10h
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple countries globally. TLX591, TLX252 and ...
Santé log10h
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by ...
Santé log13h
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share
Ensign has been a dividend-paying company since 2002.